NCT00488059View on ClinicalTrials.gov

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
HIV Infections
Interventions
DRUG

enfuvirtide [Fuzeon]

90 mg SC twice daily

DRUG

Optimized background ARV

As prescribed

DRUG

Integrase inhibitor

As prescribed

DRUG

enfuvirtide [Fuzeon]

180 mg SC once daily

Trial Locations (43)

10003

New York

10510

Briarcliff Manor

14604

Rochester

19107

Philadelphia

19601

Reading

20009

Washington D.C.

20910

Silver Spring

22003

Annandale

30309

Atlanta

30318

Atlanta

31201

Macon

32803

Orlando

33133

Miami

33139

Miami Beach

33143

South Miami

33307

Fort Lauderdale

33317

Plantation

33334

Fort Lauderdale

33408

North Palm Beach

33614

Tampa

34952

Port Saint Lucie

36201

Hobson City

36495

Safety Harbor

39912

Fort Myers

60657

Chicago

63139

St Louis

64111

Kansas City

75246

Dallas

76104

Fort Worth

77098

Houston

85006

Phoenix

90027

Los Angeles

90028

Los Angeles

90036

Los Angeles

90069

Los Angeles

94305

Stanford

95350

Modesto

02215-3318

Boston

07102

Newark

10467-2490

The Bronx

18102-7017

Allentown

00717-1563

Ponce

00909

Santurce

Sponsors

Collaborators (1)

Trimeris
All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00488059 - A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter